NCT06803485View on ClinicalTrials.gov

Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder

PHASE4RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

November 30, 2026

Conditions
Somatic Symptom Disorder (DSM-V)
Interventions
DRUG

Venlafaxine

Venlafaxine will be started at a dose of 37.5 mg/day in first week and increased to a stable dose of 75 mg/day from second week and will be continued till 8 weeks.

DRUG

Dosulepin

Dosulepin will be started at a dose of 25 mg/day in first week and increased to a stable dose of 50 mg/day from second week and will be continued till 8 weeeks.

Trial Locations (1)

751019

RECRUITING

All India Institute of Medical Sciences (AIIMS), Bhubaneswar

All Listed Sponsors
lead

All India Institute of Medical Sciences, Bhubaneswar

OTHER